Teva Pharmaceutical Industries Limited ( NYSE: TEVA) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Richard Francis - President and CEO Eric Hughes - Head of R&D and Chief ...

In the first 100 days of Modi 3.0, Sensex surged 8.2% with BSE Smallcap up 18%. Top smallcaps like Refex Industries soared 221%. Investors are cautious due to tax hikes and policy risks.

Still, more research is needed, and there's little known about how one CGRP inhibitor performs when compared with another CGRP drug. Aimovig, Ajovy, and Emgality are taken via subcutaneous injection.

In a welcome move for many patients who have a fear of needles, latest research by the Indian Institute of Technology Bombay (IIT Bombay) promises a painless syringe experience for all kinds of ...

IIT Bombay has developed needle-free shock syringes for painless, safe drug delivery, offering hope for a future without injection-related trauma. Tested on rats, it outperformed traditional needles ...

insights from industryAndrew PetersonR&D, Laboratory ProductsHamilton CompanyIn this interview, NewsMedical spoke with Hamilton Company about its innovative syringe technology, custom syringe ...

Several months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed another drug in the class – Teva’s Ajovy – in draft guidance.

Teva’s migraine drug Ajovy (fremanezumab) has moved closer to the EU market after the influential CHMP regulatory committee gave it the green light. The decision paves the way for European ...